Hemophilia in Jordan: Study of inhibitors and viral status

Jordan Medical Journal

Volumn 40, Issue 1, 2006, Pages 14-20

  Awidi, Abdalla ^a,d   Arikat, Maysa ^a   Kailani, Mona ^a   Amhasi, Baha'a ^a   Barqawi, Musa ^b   Dwairi, Mohammad ^b   Falah, Mostafa ^b   Ramahi, Mohammad ^b   Arafat, Eyad ^b   Hadadin, Esam ^c   Eid, Suhair ^c   Faouri, Sameer ^b  

^a UNIVERSITY OF JORDAN   (Jordan)

^b Ministry of Health   (Jordan)

^c KING HUSSEIN MEDICAL CENTER   (Jordan)

^d NONE   (Jordan)

Author keywords

Bethesda; ELISA; Factor VIII; Hemophilia; Inhibitors; Jordan

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; VIRUS RNA;

ADULT; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNOASSAY; INFANT; JORDAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD;

EID: 33745479563     PISSN: 04469283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol. 2004; 127: 379-391.
2. Kreuz W, Ettingshavsen CE, Auerswald G, Saguer IM, Becker S, Funk M et al. Epidemiology of inhibitors and current treatment strategies. Haematologica. 2003; 88(9): 17-20.
3. Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995; 74(6): 1402-1406.
4. Fakharzadeh SS, Kazazian HH. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemos. 2000; 26(2): 167-171.
5. Giannelli F, Choo KH, Rees DJG, Boyed Y, Rizza CR. Gene deletions in patients with hemophilia B and anti- factor IX antibodies. Nature. 1983; 303: 181-182.
6. Nilsson IM, Bernorp E, Lofqvist T, Petterson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992; 232: 25-32.
7. Possible transfusion-associated Acquired Immune Deficiency Syndrome (AIDS)-California. MMWR Morb Mortal Wkly Rep. 1982; 31: 652-654.
8. Bamber M, Murray A, Arborgh BA, Scheuer PJ, Kernoff PB, Thomas HC, Sherlok S. Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders. Gut. 1981; 22: 854-859.
9. El-Khateeb MS, Awidi AS, Tarawneh MS, Madanat F. Hepatitis in patients with bleeding disorders in Jordan. J Trop Pediatr. 1988; 34(3): 137-138.
10. Loosing T, Kasper C, Feinstein D. Detection of factor VIII inhibitors with partial thromboplastin time. Blood. 1977; 49: 793-795.
11. Sahud MA, M.D. Laboratory diagnosis of inhibitors. Semin thromb Hemo. 2000; 26: 195-203.
12. Kasper CK, Aledort LM, Counts RB, Aronson D, Edson JR. Fratantoni J et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975; 34: 869-872.
13. Verbruggen B, Novakova I, Wessels H, Boezeman J, Van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII.C inhibitors: improved specificity and reliability. Thromb Haemost. 1995; 73: 247-251.
14. Ewing N, Kasper C. In-vitro detection of mild inhibitors to factor VIII in haemophilia. Am J Clin Path. 1982; 77: 793-797.
15. Martin PG, Sukhu K, Chambers E, Giangrande PL. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory Antibodies in haemophiliacs. Clin Lab Haematol. 1999; 21: 125-128.
16. Gringeri A, Mantovani LC, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated inhibitors: the COCIS study group. Blood. 2003; 102(7): 2358-2363.
17. Dimichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia. 2004; 10: (4): 140-145.
18. Rosendaal FR, Varelcamp I, Smit C, Brocker-Vriends AHJT et al. Mortality and cause of death in Dutch hemophiliacs. 1973-1986. Haemophilia. 2004; 10: (4): 140-145.
19. M. Popovic, MG. Sarngadharan, E. Read, RC. Gallo. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224: 497-500.
20. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Mover LA et al. The prevalence of hepatitis C virus infection in the United States. 1988 through 1994. N Engl J Med. 1999; 341: 556-562.
21. Barre'-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for Acquired Immune Deficiency Syndrome (AIDS). Science. 1983; 220: 868-871.
22. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244: 359-362.